Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANIFEST-2 phase 3 trial of pelabresib plus ruxolitinib versus placebo plus ruxolitinib in JAK inhibitor-naive myelofibrosis
MOH_2022-04-25_010614Phase 3Active, not recruiting
- Sponsor
- Constellation Pharmaceuticals
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelofibrosis (MF) comparing Pelabresib + ruxolitinib with Placebo + ruxolitinib (2 arms). Primary endpoint: Spleen volume response at week 24. Started Apr 2022; status: active, not recruiting.
02
Drugs
pelabresibruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on MOH_2022-04-25_010614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-04-25_010614.